{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,21]],"date-time":"2026-10-21T14:04:28Z","timestamp":1792591468294,"version":"4.5.0"},"reference-count":36,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,3,1]],"date-time":"2026-03-01T00:00:00Z","timestamp":1772323200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,3,1]],"date-time":"2026-03-01T00:00:00Z","timestamp":1772323200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,3,27]],"date-time":"2026-03-27T00:00:00Z","timestamp":1774569600000},"content-version":"vor","delay-in-days":26,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100004348","name":"Stockholms l\u00e4ns landsting","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100004348","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","ejpn-journal.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["European Journal of Paediatric Neurology"],"published-print":{"date-parts":[[2026,3]]},"DOI":"10.1016\/j.ejpn.2026.03.009","type":"journal-article","created":{"date-parts":[[2026,3,27]],"date-time":"2026-03-27T08:18:38Z","timestamp":1774599518000},"page":"78-83","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":1,"special_numbering":"C","title":["Cenobamate use for drug-resistant epilepsy in children: A real-world single-center study"],"prefix":"10.1016","volume":"61","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-1183-150X","authenticated-orcid":false,"given":"Ronny","family":"Wickstr\u00f6m","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maria","family":"Dahlin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mattias","family":"\u00c5berg","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1242-5260","authenticated-orcid":false,"given":"Tommy","family":"St\u00f6dberg","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"2","key":"10.1016\/j.ejpn.2026.03.009_bib1","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1684\/epd.2015.0736","article-title":"Incidence, prevalence and aetiology of seizures and epilepsy in children","volume":"17","author":"Camfield","year":"2015","journal-title":"Epileptic Disord."},{"issue":"9","key":"10.1016\/j.ejpn.2026.03.009_bib2","doi-asserted-by":"crossref","first-page":"935","DOI":"10.1007\/s40263-021-00827-8","article-title":"The pharmacology and clinical efficacy of antiseizure medications: from bromide salts to cenobamate and beyond","volume":"35","author":"L\u00f6scher","year":"2021","journal-title":"CNS Drugs"},{"issue":"5","key":"10.1016\/j.ejpn.2026.03.009_bib3","doi-asserted-by":"crossref","first-page":"314","DOI":"10.1056\/NEJM200002033420503","article-title":"Early identification of refractory epilepsy","volume":"342","author":"Kwan","year":"2000","journal-title":"N. Engl. J. Med."},{"issue":"3","key":"10.1016\/j.ejpn.2026.03.009_bib4","doi-asserted-by":"crossref","first-page":"279","DOI":"10.1001\/jamaneurol.2017.3949","article-title":"Treatment outcomes in patients with newly diagnosed epilepsy treated with established and new antiepileptic drugs: a 30-Year longitudinal cohort study","volume":"75","author":"Chen","year":"2018","journal-title":"JAMA Neurol."},{"issue":"22","key":"10.1016\/j.ejpn.2026.03.009_bib5","doi-asserted-by":"crossref","first-page":"e2311","DOI":"10.1212\/WNL.0000000000009530","article-title":"Randomized phase 2 study of adjunctive cenobamate in patients with uncontrolled focal seizures","volume":"94","author":"Chung","year":"2020","journal-title":"Neurology"},{"issue":"1","key":"10.1016\/j.ejpn.2026.03.009_bib6","doi-asserted-by":"crossref","first-page":"38","DOI":"10.1016\/S1474-4422(19)30399-0","article-title":"Safety and efficacy of adjunctive cenobamate (YKP3089) in patients with uncontrolled focal seizures: a multicentre, double-blind, randomised, placebo-controlled, dose-response trial","volume":"19","author":"Krauss","year":"2020","journal-title":"Lancet Neurol."},{"issue":"6","key":"10.1016\/j.ejpn.2026.03.009_bib7","doi-asserted-by":"crossref","first-page":"609","DOI":"10.1007\/s40263-021-00819-8","article-title":"Pharmacology of cenobamate: mechanism of action, pharmacokinetics, drug-drug interactions and tolerability","volume":"35","author":"Roberti","year":"2021","journal-title":"CNS Drugs"},{"key":"10.1016\/j.ejpn.2026.03.009_bib8","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejphar.2020.173117","article-title":"Positive allosteric modulation of GABA(A) receptors by a novel antiepileptic drug cenobamate","volume":"879","author":"Sharma","year":"2020","journal-title":"Eur. J. Pharmacol."},{"key":"10.1016\/j.ejpn.2026.03.009_bib9","doi-asserted-by":"crossref","first-page":"175","DOI":"10.1016\/j.ejphar.2019.05.007","article-title":"Effects of cenobamate (YKP3089), a newly developed anti-epileptic drug, on voltage-gated sodium channels in rat hippocampal CA3 neurons","volume":"855","author":"Nakamura","year":"2019","journal-title":"Eur. J. Pharmacol."},{"issue":"Suppl 1","key":"10.1016\/j.ejpn.2026.03.009_bib10","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1111\/epi.18303","article-title":"Cenobamate efficacy in specific populations","volume":"66","author":"Klein","year":"2025","journal-title":"Epilepsia"},{"key":"10.1016\/j.ejpn.2026.03.009_bib11","doi-asserted-by":"crossref","DOI":"10.1111\/epi.18586","article-title":"Real-world use of cenobamate in pediatric focal epilepsies and developmental epileptic encephalopathies: a multicenter retrospective series","author":"Soto-Insuga","year":"2025","journal-title":"Epilepsia"},{"key":"10.1016\/j.ejpn.2026.03.009_bib12","doi-asserted-by":"crossref","first-page":"201","DOI":"10.1016\/j.pediatrneurol.2024.09.023","article-title":"Cenobamate's efficacy for seizure treatment in Tuberous sclerosis complex","volume":"161","author":"Aungaroon","year":"2024","journal-title":"Pediatr. Neurol."},{"key":"10.1016\/j.ejpn.2026.03.009_bib13","doi-asserted-by":"crossref","DOI":"10.1016\/j.yebeh.2022.108679","article-title":"Adjunctive use of cenobamate for pediatric refractory focal-onset epilepsy: a single-center retrospective study","volume":"130","author":"Varughese","year":"2022","journal-title":"Epilepsy Behav."},{"issue":"6","key":"10.1016\/j.ejpn.2026.03.009_bib14","doi-asserted-by":"crossref","first-page":"1804","DOI":"10.1111\/epi.18338","article-title":"Updated classification of epileptic seizures: position paper of the international league against epilepsy","volume":"66","author":"Beniczky","year":"2025","journal-title":"Epilepsia"},{"key":"10.1016\/j.ejpn.2026.03.009_bib15","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1016\/j.pediatrneurol.2022.01.001","article-title":"Initial real-world experience with cenobamate in adolescents and adults: a single center experience","volume":"129","author":"Elliott","year":"2022","journal-title":"Pediatr. Neurol."},{"key":"10.1016\/j.ejpn.2026.03.009_bib16","doi-asserted-by":"crossref","DOI":"10.3389\/fneur.2022.950171","article-title":"Real-world experience treating pediatric epilepsy patients with cenobamate","volume":"13","author":"Makridis","year":"2022","journal-title":"Front. Neurol."},{"issue":"2","key":"10.1016\/j.ejpn.2026.03.009_bib17","doi-asserted-by":"crossref","DOI":"10.1212\/CPJ.0000000000200133","article-title":"Cenobamate in generalized epilepsy and combined generalized and focal epilepsy","volume":"13","author":"Agashe","year":"2023","journal-title":"Neurol., Clin. Pract."},{"issue":"4","key":"10.1016\/j.ejpn.2026.03.009_bib18","doi-asserted-by":"crossref","first-page":"1119","DOI":"10.1111\/epi.18257","article-title":"Cenobamate as add-on treatment for SCN8A developmental and epileptic encephalopathy","volume":"66","author":"Gjerulfsen","year":"2025","journal-title":"Epilepsia"},{"issue":"5","key":"10.1016\/j.ejpn.2026.03.009_bib19","doi-asserted-by":"crossref","first-page":"1519","DOI":"10.1111\/epi.18308","article-title":"A multicenter cohort study on the efficacy, retention, and tolerability of cenobamate in patients with developmental and epileptic encephalopathies","volume":"66","author":"Buhleier","year":"2025","journal-title":"Epilepsia"},{"issue":"6","key":"10.1016\/j.ejpn.2026.03.009_bib20","doi-asserted-by":"crossref","first-page":"e83","DOI":"10.1111\/epi.18426","article-title":"Lack of effectiveness and seizure worsening with cenobamate in pediatric patients with Dravet syndrome","volume":"66","author":"Cagigal","year":"2025","journal-title":"Epilepsia"},{"key":"10.1016\/j.ejpn.2026.03.009_bib21","volume":"vol. 13","author":"Lobanov","year":"2025"},{"issue":"5","key":"10.1016\/j.ejpn.2026.03.009_bib22","doi-asserted-by":"crossref","DOI":"10.1002\/brb3.70567","article-title":"Cenobamate in real-word scenario: results on efficacy, side effects, and retention rate in a single center retrospective study","volume":"15","author":"Badr","year":"2025","journal-title":"Brain Behav"},{"key":"10.1016\/j.ejpn.2026.03.009_bib23","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1016\/j.seizure.2025.05.002","article-title":"Efficacy and safety of cenobamate: a multicenter, retrospective evaluation of real-world clinical practice","volume":"130","author":"Bosak","year":"2025","journal-title":"Seizure"},{"key":"10.1016\/j.ejpn.2026.03.009_bib24","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.seizure.2023.09.006","article-title":"Real-world experience with cenobamate: a systematic review and meta-analysis","volume":"112","author":"Makridis","year":"2023","journal-title":"Seizure"},{"issue":"10","key":"10.1016\/j.ejpn.2026.03.009_bib25","doi-asserted-by":"crossref","first-page":"e989","DOI":"10.1212\/WNL.0000000000200792","article-title":"Long-term efficacy and safety from an open-label extension of adjunctive cenobamate in patients with uncontrolled focal seizures","volume":"99","author":"Klein","year":"2022","journal-title":"Neurology"},{"issue":"4","key":"10.1016\/j.ejpn.2026.03.009_bib26","doi-asserted-by":"crossref","first-page":"1685","DOI":"10.1007\/s40120-025-00779-x","article-title":"Cenobamate for adjunctive treatment in adult and pediatric patients with refractory lennox-gastaut syndrome: a retrospective chart review","volume":"14","author":"Keough","year":"2025","journal-title":"Neurol Ther"},{"issue":"12","key":"10.1016\/j.ejpn.2026.03.009_bib27","doi-asserted-by":"crossref","first-page":"e164","DOI":"10.1111\/epi.17427","article-title":"Successful treatment of adult Dravet syndrome patients with cenobamate","volume":"63","author":"Makridis","year":"2022","journal-title":"Epilepsia"},{"issue":"4","key":"10.1016\/j.ejpn.2026.03.009_bib28","doi-asserted-by":"crossref","first-page":"1705","DOI":"10.1007\/s40120-022-00400-5","article-title":"Dose adjustment of concomitant antiseizure medications during cenobamate treatment: expert opinion consensus recommendations","volume":"11","author":"Smith","year":"2022","journal-title":"Neurol Ther"},{"issue":"4","key":"10.1016\/j.ejpn.2026.03.009_bib29","doi-asserted-by":"crossref","first-page":"e36","DOI":"10.1111\/epi.17515","article-title":"A retrospective non-interventional study evaluating the pharmacokinetic interactions between cenobamate and clobazam","volume":"64","author":"Elakkary","year":"2023","journal-title":"Epilepsia"},{"key":"10.1016\/j.ejpn.2026.03.009_bib30","doi-asserted-by":"crossref","DOI":"10.1016\/j.yebeh.2023.109156","article-title":"The cenobamate-clobazam interaction- evidence of synergy in addition to pharmacokinetic interaction","volume":"142","author":"Osborn","year":"2023","journal-title":"Epilepsy Behav."},{"issue":"6","key":"10.1016\/j.ejpn.2026.03.009_bib31","doi-asserted-by":"crossref","first-page":"1099","DOI":"10.1111\/epi.16525","article-title":"Cenobamate (YKP3089) as adjunctive treatment for uncontrolled focal seizures in a large, phase 3, multicenter, open-label safety study","volume":"61","author":"Sperling","year":"2020","journal-title":"Epilepsia"},{"issue":"1","key":"10.1016\/j.ejpn.2026.03.009_bib32","doi-asserted-by":"crossref","first-page":"139","DOI":"10.1111\/epi.17134","article-title":"Long-term individual retention with cenobamate in adults with focal seizures: pooled data from the clinical development program","volume":"63","author":"Sander","year":"2022","journal-title":"Epilepsia"},{"issue":"9","key":"10.1016\/j.ejpn.2026.03.009_bib33","doi-asserted-by":"crossref","first-page":"2142","DOI":"10.1111\/epi.17007","article-title":"Long-term safety of adjunctive cenobamate in patients with uncontrolled focal seizures: open-label extension of a randomized clinical study","volume":"62","author":"French","year":"2021","journal-title":"Epilepsia"},{"issue":"3","key":"10.1016\/j.ejpn.2026.03.009_bib34","doi-asserted-by":"crossref","first-page":"321","DOI":"10.1007\/s40263-025-01158-8","article-title":"Post-marketing experience with cenobamate in the treatment of focal epilepsies: a multicentre cohort study","volume":"39","author":"Strzelczyk","year":"2025","journal-title":"CNS Drugs"},{"issue":"4","key":"10.1016\/j.ejpn.2026.03.009_bib35","doi-asserted-by":"crossref","first-page":"296","DOI":"10.1016\/j.seizure.2007.01.004","article-title":"Comparative retention rates and long-term tolerability of new antiepileptic drugs","volume":"16","author":"Chung","year":"2007","journal-title":"Seizure"},{"key":"10.1016\/j.ejpn.2026.03.009_bib36","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1016\/j.eplepsyres.2017.10.008","article-title":"Long-term retention rates for antiepileptic drugs: a review of long-term extension studies and comparison with brivaracetam","volume":"138","author":"Toledo","year":"2017","journal-title":"Epilepsy Res."}],"container-title":["European Journal of Paediatric Neurology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1090379826000279?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1090379826000279?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,5,14]],"date-time":"2026-05-14T22:36:40Z","timestamp":1778798200000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1090379826000279"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,3]]},"references-count":36,"alternative-id":["S1090379826000279"],"URL":"https:\/\/doi.org\/10.1016\/j.ejpn.2026.03.009","relation":{},"ISSN":["1090-3798"],"issn-type":[{"value":"1090-3798","type":"print"}],"subject":[],"published":{"date-parts":[[2026,3]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Cenobamate use for drug-resistant epilepsy in children: A real-world single-center study","name":"articletitle","label":"Article Title"},{"value":"European Journal of Paediatric Neurology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ejpn.2026.03.009","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 The Authors. Published by Elsevier Ltd on behalf of European Paediatric Neurology Society.","name":"copyright","label":"Copyright"}]}}